Glaukos GKOS
First Signal's file · in 1 issue · All companies
Implants and drugs for glaucoma
Every time it made the issue
We cover a company only when it moves enough to matter. Each row is one of those days, what we made of it, and how the stock did over the next 5 and 20 trading days, next to the S&P 500.
| Date | Where | Move | Our read | 5 days later | 20 days later |
|---|---|---|---|---|---|
| Thu, Oct 29, 2026 | Earnings | +33.6% | Revenue of $211 million beat the $168 million expected, and it raised its full-year forecast, via CNBC. Best day since 2018. | to come | to come |
Its biggest days of the past ten years
| Best days | Move |
|---|---|
| Wed, Aug 29, 2018 | +40.3% |
| Thu, Oct 29, 2026 | +33.6% |
| Thu, Dec 14, 2023 | +25.4% |
| Worst days | Move |
|---|---|
| Fri, Feb 28, 2020 | −28.5% |
| Wed, Jul 14, 2021 | −21.4% |
| Fri, Feb 21, 2025 | −20.0% |
How it took its last 8 reports
The stock's move in the first session after each quarterly report. Next report: Wednesday, February 17, 2027.
| Results filed | Next session |
|---|---|
| Wed, Oct 28, 2026 | +33.6% |
| Wed, Jul 29, 2026 | +4.2% |
| Wed, Apr 29, 2026 | +22.8% |
| Tue, Feb 17, 2026 | +13.5% |
| Wed, Oct 29, 2025 | +13.9% |
| Wed, Jul 30, 2025 | −8.5% |
| Wed, Apr 30, 2025 | −11.4% |
| Thu, Feb 20, 2025 | −20.0% |
Moves are daily closing prices. Past moves don't predict future ones.